CLN3 disease (Spielmeyer-Vogt-Sjogren-Batten disease, previously known as classic juvenile neuronal ceroid lipofuscinosis, NCL) is a pediatric-onset progressive neurodegenerative disease characterized by progressive vision loss, seizures, loss of cognitive and motor function, and early death. While no precise biochemical mechanism or therapies are known, the pathogenesis of CLN3 disease involves intracellular calcium accumulation that may trigger apoptosis. Our prior work in in vitro cell models of CLN3 deficiency suggested that FDA-approved calcium channel antagonists may have therapeutic value. To further evaluate the potential efficacy of this approach in an otherwise untreatable disorder, we sought to compare the therapeutic effects and underlying mechanisms in an animal model of CLN3 disease. Here, we used the wellcharacterized XT7 complete cln-3 knockout strain of C. elegans to evaluate the therapeutic efficacy of calcium channel antagonist therapy in a living animal model of Batten disease. Therapeutic effects of five calcium channel antagonists were evaluated on XT7 animal lifespan and in vivo mitochondrial physiology. Remarkably, maximal therapeutic efficacy in this model animal was observed with 1 μM flunarizine, the identical concentration previously identified in cell-based neuronal models of CLN3 disease. Specifically, flunarizine rescued the short lifespan of XT7 worms and prevented their pathophysiologic mitochondrial accumulation. These results confirm the treatment efficacy and dosing of flunarizine in cln-3 disease in a translational model organism. Clinical treatment trials in CLN3 human patients are now needed to test the dosing regimen and efficacy of flunarizine in individuals suffering with this otherwise untreatable and ultimately lethal neurologic disease.
Introduction
The neuronal ceroid-lipofuscinoses (NCLs) comprise a genetically heterogeneous group of progressive neurodegenerative, mostly autosomal recessive disorders for which no treatments exist. Some clinical trials are in progress, however, including the immunosuppressive drug mycophenolate, which has been shown to decrease neuroinflammation and improve motor performance in Cln3 −/− mice (Seehafer et al 2011; Drack et al 2015) and for which a phase 2 short-term clinical trial has been completed (NCT01399047; no results have yet been published), as well as enzyme replacement therapy in CLN2 disease (NCT92678689; no results have yet been published). The NCLs are clinically characterized by variable onset of progressive vision loss leading to blindness, seizures, loss of motor and cognitive function, and premature death. Their shared histopathologic signature is neuronal cell death with accumulation of cytoplasmic autofluorescent storage material (Haltia 2003) . CLN3 disease (Spielmeyer-Vogt-Sjogren-Batten disease, previously known as classic juvenile NCL, OMIM 204200) is a pediatriconset NCL caused by recessive mutations in CLN3 located on chromosome 16. Most children with this disease have normal development until between 4 and 7 years of age, when they present with progressive visual loss, seizures, and relentless motor and cognitive decline ultimately leading to death in the mid to late 20s and early 30s.
Although the CLN3 gene is well-characterized, the cellular pathway through which abnormal CLN3 protein leads to neuronal cell death is unclear (Phillips et al 2005; Rakheja et al 2008; Bennett and Rakheja 2013) . CLN3 protein (CLNP, Battenin) is a multi-spanning integral membrane protein that localizes in part to membrane lipid rafts. CLN3 protein functions to insert a double bond into the palmitate molecule of palmitoylated membrane-associated protein(s) (Rakheja et al 2004; Narayan et al 2006a) . However, no physiological protein partners for this palmitate desaturation or specific pathway(s) involved have yet been identified. Downstream of the desaturase effect, abnormal intracellular calcium accumulation may trigger apoptosis, a phenomenon which may be prevented by increased CLNP expression (Lane et al 1996; Puranam et al 1999; Dhar et al 2002; Persaud-Sawin et al 2002; Persaud-Sawin and Boustany 2005; Narayan et al 2006b) . Further, it appears that calcium-induced cytotoxicity that occurs with loss of CLNP function may be mediated by the neuronal calcium sensor calsenilin (Chang et al 2007) .
Given the calcium induced cytotoxicity of this disorder, we previously screened known calcium-channel modulators for their ability to lower the calcium elevations that occur in CLN3 knock down SH-SY5Y neuroblastoma cells. We identified several predominantly L-type calcium channel antagonists as candidate drugs to lower intracellular calcium levels in this model (An Haack et al 2011) . Amlodipine further prevented apoptotic cell death in siRNA-inhibited CLN3P knockdown primary rat cortical neurons by normalizing elevated intracellular calcium levels (Warnock et al 2013) . Thus, calcium channel blockers appeared to be promising therapeutic agents within two in vitro models of CLN3 disease.
A CLN3 triple knockout Caenorhabditis elegans strain has previously been shown to serve as a translational animal model of Batten disease. Indeed, the nematode's simple nervous system and short lifespan (median lifespan of wild-type N2 Bristol strain is ∼2 weeks) serves as an intermediate model organism between yeast and mouse models (de Voer et al 2005) . Three homologues of CLN3 exist in C. elegans (cln3-1, cln3-2, cln3-3), each of which is encoded by a different gene and expressed at different life stages and anatomical locations (de Voer et al 2005) . The cln-3 triple knockout strain is named XT7 [cln-3.2(gk41)I; cln-3.1(pk479)V; cln-3.3(gk118)V] and was previously shown to have a shortened lifespan (de Voer et al 2005) . Here, we used the XT7 complete cln-3 knockout strain to evaluate the therapeutic efficacy of calcium channel antagonist therapy in a living animal model of Batten disease.
Methods

C. elegans strain selection
C. elegans strain, XT7, that harbors deletion mutations in all three nuclear-encoded cln-3 gene homologues [cln-3.2(gk41)I; cln-3.1(pk479)V; cln-3.3(gk118)V] was studied (as was kindly provided by PEM Taschner) (de Voer et al 2005) . N2 Bristol was the wild-type control strain studied, which was obtained as a stable line from the Caenorhabditis Genetics Center (CGC, www.wormbase.org).
C. elegans lifespan analyses following calcium channel antagonist treatment during development and/or young adulthood Animals were maintained in 20°C incubators. Synchronized nematode cultures were initiated by bleaching young adults to obtain eggs. Collected eggs were allowed to hatch overnight on 10 cm, unspread, nematode growth media (NGM) plates, after which L1-arrested larvae were transferred to 10 cm NGM plates spread with OP50 E. coli, drug treatment, and/or appropriate DMSO-only buffer control.
Drug treatment was applied as follows: amlodipine, flunarizine, nicardipine, nifedipine, and nimodipine were each dissolved in 100 % DMSO to a stock concentration of 1 mM and added to plates to achieve a final concentration on NGM plates of 1 μM, with a final DMSO concentration on NGM plates of 0.1 %. For dose-curve lifespan studies with the lead candidate based on initial drug screen, flunarizine at concentrations of 10, 1, 0.5, 0.1 μM was used, with final DMSO concentration on NGM plates of 1 %. Worms were subsequently transferred to fresh NGM spread plates each week (i.e., weekly redosing occurred of drug or buffer-only control treatments to account for photosensitivity of calcium channel antagonists).
Upon reaching the first day of egg laying, synchronous young adult XT7 worms were moved to fresh 3.5 cm NGM plates seeded with OP50 bacteria and treated with a given drug. The same volume of water or DMSO was added to control animal plates. For purposes of higher-throughput lifespan screening, in order to remove the offspring of the nematodes under study from reaching adulthood, fluorodeoxyuridine (FUDR) was added to OP50-spread NGM plates to a final concentration of 100 mg/ml. Approximately 60 nematodes were studied per experimental condition, divided on three 3.5 cm NGM plates. Mortality was confirmed by stimulating nematodes lightly with a platinum wire; if the nematode did not move after stimulations, it was scored as dead and removed from the plate. Worms that died of protruding/bursting vulva, bagging, or crawling off the agar were censored. Lifespan analyses were statistically analyzed in GraphPad Prism 5.0 as previously described (McCormack et al 2015a) .
Relative fluorescence microscopy quantitation of calcium channel antagonist treatments on mitochondrial mass Mitochondrial mass (MitoTracker Green FM, MTG) analyses were performed at 20°C using in vivo terminal pharyngeal bulb relative fluorescence quantitation, as previously described (Dingley et al 2010; McCormack et al 2015b) . Briefly, worms were treated with either 1 μM flunarizine or 0.1 % DMSO buffer control from the early development L1larval stage. Upon reaching the first day of egg-laying, synchronous populations of young adults were moved to 3.5 cm NGM plates spread with OP50 E. coli, either 1 μM flunarizine or 0.1 % DMSO buffer control, and 10 μM MitoTracker Green FM (to evaluate relative mitochondrial mass) for 24 h. The next day, worms were transferred by worm picks onto 3.5 cm plates spread with OP50 E. coli without dye for 1 h, to allow clearing of residual fluorescent dye from their gastrointestinal tract. Worms were then paralyzed in situ with 5 mg/ml levamisole. Photographs were taken in a darkened room at 160× magnification with a Cool Snap cf2 camera (Nikon, Melville, NY). A GFP2 filter set (Leica) was used for MitoTracker Green FM. Respective exposure time was 300 ms for MitoTracker Green FM. The resulting images were background subtracted, and the nematode terminal pharyngeal bulb was manually circled to obtain mean intensity of the region by using Fiji Is Just ImageJ (Schindelin et al 2012) . Fluorescence data for each strain were normalized to its same day control to account for day-to-day variation. A minimum of three independent experiments of approximately 50 animals per replicate were studied per strain per dye. Statistical analyses of the calculated difference in the mean fluorescence intensity between strains or under different experimental conditions were assessed by mixed-effect ANOVA using built-in code in MATLAB (Natick, MA, USA). This analysis was used to account for any potential batch effect due to samples being experimentally prepared, processed, and analyzed on different days, by including a batch random effect in the model. A statistical significance threshold was set at p < 0.05.
Results
Flunarizine [1 μM] had the greatest effect of five calcium channel antagonists screened on rescuing the short lifespan of XT7 mutant worms XT7 mutant worms were found to be significantly short-lived relative to wild-type (N2 Bristol) worms, consistent with prior report (de Voer et al 2005) . Specifically, the XT7 strain had a median lifespan of 8.6 days, whereas wild-type N2 Bristol worms had a median lifespan of 11.2 days (23 % reduction in XT7, log-rank/Mantel-Cox test, p = 0.002). All five calcium channel antagonists tested led to an increase in the median lifespan, though only one drug, flunarizine, reached statistical significance based on the log-rank Mantel-Cox test (p < 0.05). Flunarizine also led to the greatest increase in the XT7 strain in mean (10.3 days vs 11.8 days), median (8.6 days vs 10.4 days), and maximum (22 days vs 24 days) lifespan (Fig. 1) . Based on the results from the five drug screen on XT7 lifespan using the 1 μM dose of each drug that was found to be effective in the Fig. 1 XT7 animal lifespan screening of five calcium channel antagonists, which had shown to normalize increased intracellular calcium levels in rat neuronal models. Of five drugs screened, the 1 μM dose of flunarizine was the most effective in rescuing mean, median, and maximum lifespans of XT7 strain toward that of wild-type N2 worms. N = 60 worms per condition. *, p < 0.05; ***, p < 0.001 compared to XT7 strain in vitro cellular models (An Haack et al 2011) , flunarizine was selected for further dose effect studies of four concentrations. In two independent trials, 1 μM flunarizine remained the optimum concentration to rescue XT7 mean, median, and maximum Fig. 2 XT7 animal lifespan dose-span evaluation of flunarizine, which was the most effective calcium channel antagonist drug in rescuing the shortened lifespan of XT7 strain. 1 μM dose of flunarizine remained the most effective dose in rescuing mean, median, and maximum lifespans of XT7 strain toward that of wild-type N2 worms. N = 60 worms per condition. *, p < 0.05; ***, p < 0.001 compared to XT7 strain Fig. 3 In vivo mitochondrial mass evaluation of flunarizine in XT7 animals. a Representative image of C. elegans stained with MTG, where manual microscopic quantitation of relative MTG fluorescence intensity was limited to the 8-cell terminal pharyngeal bulb highlighted as the red circle. b In day 1 young adults, XT7 mutant worms had 10 % increased mitochondrial mass compared to wild-type N2 worms. 1 μM flunarizine treatment initiated in early development from the L1 larval stage prevented the increased mitochondrial mass that occurs in XT7 worms (7.1 % decrease from XT7 strain). Approximately 60 nematodes were studied per experimental condition, and each condition was conducted in biological triplicates (n = 3). Bars and error bars convey mean +/− SEM. *, p < 0.05 lifespan (Fig. 2) . Thus, these in vivo animal data support earlier in vitro studies suggesting that calcium channel antagonists have therapeutic efficacy to extend lifespan in this neurodegenerative disease.
Flunarizine reverses mitochondrial mass accumulation in day 1 young adult XT7 worms
Altered mitochondrial physiology has previously been implicated in the pathogenesis of CLN3 disease, with accumulation of subunit C of mitochondrial respiratory chain complex V (Palmer et al 1989) . While no antibody is available to test complex V accumulation in C. elegans, we sought to determine whether overall mitochondrial mass was altered in this model. Indeed, day 1 young adult XT7 mutant worms had a 10 % increased mitochondrial mass (p < 0.05) as evaluated by fluorescence microscopy of relative mitotracker green fluorescence compared to wild-type N2 worms (Fig. 3) , suggestive that XT7 worms having mitochondrial proliferation. Remarkably, 1 μM flunarizine treatment from development (i.e., L1 larval stages) prevented mitochondrial mass accumulation in this model (7.1 % decrease from XT7 strain, p < 0.05) (Fig. 3) . Thus, these data support earlier reports of increased mitochondrial mass occurring in CLN3 disease, with this pathophysiologic aspect of the disease here prevented by 1 μM flunarizine treatment.
Discussion
CLN3 disease is a progressive neurodegenerative disorder whose pathogenesis is incompletely understood and for which no therapies exist. Our studies described here in a validated XT7 animal model of CLN3-based Batten disease due to triple knockout of three cln-3 homologous genes in C. elegans recapitulate both the short lifespan of the mutant strain and a novel indicator of its having abnormal mitochondrial proliferation. Most importantly, we show that the equivalent molar dose of a calcium channel antagonist, flunarizine (1 μM), that was shown to normalized increased intracellular calcium levels in cellular neuronal model (An Haack et al 2011) , effectively rescues the shortened lifespan of the XT7 cln-3 triple gene knockout strain. It is possible that some other agents in this class could have additional physiologic benefit that was not evident on lifespan analysis with weekly redosing in the C. elegans model animal, as for example nifedipine is known to be unstable and subject to decomposition with photobleaching. However, we also show that 1 μM flunarizine prevents mitochondrial accumulation in the XT7 strain. Thus, we conclude that flunarizine is a promising calcium channel antagonist to consider evaluating in human CLN3 disease.
Flunarizine's exact mechanism of action in improving cell and animal viability in CLN3 disease is not entirely clear. However, we postulate that flunarizine aids in the efflux into JNCL cells of calcium that is dysregulated as a downstream sequelae of the primary effect of deficient CLN3 protein, which involves failure of C16 desaturation of an unspecified in vivo target, and as we previously discovered in primary rat neurons, reduces neuronal apoptosis (Warnock et al 2013) . The safety profile in humans of the calcium channel blockers used in these studies is well-known. The clinical indications for these agents have typically involved cardiovascular (arrhythmias, peripheral vascular disease) rather than neurodegenerative ones (Elkayam et al 1993; Elkayam 1998; de Vries et al 2000; Trepakova et al 2006; Cao et al 2016; Lepcha et al 2014; Hasan et al 2013) , although they have also been shown to have activity in central neurologic conditions such as migraines, vertigo, and as an adjunctive therapy for epilepsy. Repurposing FDA approved drugs in rare diseases can improve outcomes; for example, the use of the anti-rheumatic agent auranofin was used in gastrointenstinal stromal tumor (GIST) (Pessetto et al 2013) . Additional studies are looking to repurpose FDA approved drugs in orphan disease treatments (Beaulieu et al 2012; Xu and Coté 2011) . Overall, we anticipate that these translational model animal studies to confirm treatment efficacy and optimize treatment dose of flunarizine in cln-3 disease can be rapidly translated to clinical treatment trials in CLN3 human patients suffering with this otherwise untreatable and lethal severe neurologic disease.
